<DOC>
	<DOCNO>NCT02842814</DOCNO>
	<brief_summary>Whether systemic lupus erythematosus ( SLE ) patient stable disease withdraw glucocorticoid ( GC ) ? How relapse risk ? What risk factor disease flare ? All unclear . Long-course GC treatment lot side-effects even sustain low dose . The aim study explore relapse risk GC withdrawal SLE patient stable disease one year establish predictive model flare risk stratification .</brief_summary>
	<brief_title>Prediction Relapse Risk Stable Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Systemic lupus erythematosus ( SLE ) chronic autoimmune disease relapsing-remitting course . For patient remission , glucocorticoid ( GC ) use maintain low dose long time fear disease flare . Long-term GC could bring lot side-effects even low dose . Whether patient stable disease withdraw GC ? How relapse risk ? What risk factor disease flare ? All remain unclear . The aim study explore relapse risk GC withdrawal SLE patient stable disease establish predictive model risk stratification . Meanwhile investigator aim testify effect hydroxychloroquine prevent SLE relapse . This study open-labeled randomize controlled clinical trial .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>SLE diagnosis fulfil Systemic Lupus International Collaborating Clinic revision American College Rheumatology Classification Criteria SLE Disease stabilize ≥ 1 year SELENASLEDAI ≤ 3 Antidouble strand DNA negative IF measurement ≤ 200IU/ml ELISA method Complement 3 ( C3 ) ≥ 0.5*lower limit normal range , fluctuation C3 le 10 % within last year 24 hour urine protein ≤ 0.5g Prednisone ( equivalent ) ≤ 7.5mg/d 6 month No use immunosuppressant include CsA , MMF , CTX , FK506 , LEF , MTX recent 6 month . But hydroxychloroquine ( HCQ ) permit use Never use biologic agent include Rituximab , Belimumab , Epratuzumab No severe organ involvement recent 2 year include lupus encephalosis , diffuse alveolar hemorrhage , thrombotic thrombocytopenia purpura , rapid progressive glomerulonephritis , severe thrombocytopenia , severe hemolytic anemia , myocardial involvement , myeleterosis severe peripheral neuropathy Active SLE In pregnancy breastfeeding , plan pregnancy Plan surgery recent 6 month Current infection History malignancy Severe organ dysfunction complication Unable follow Inappropriate enrol Psoriasis , porphyria , arrhythmia eye diseases contradict HCQ usage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Stable</keyword>
	<keyword>Relapse Risk</keyword>
	<keyword>Glucocorticoid Withdrawal</keyword>
</DOC>